基于肠道菌群的慢性肾病药物治疗研究现状  

Research progress of drug therapy for chronic kidney disease based on intestinal flora

作　　者：全晶晶 黄志军[1,2] QUAN Jing-jing;HUANG Zhi-jun(Department of Nephrology,The Third Xiangya Hospital,Central South University,Changsha 410013,Hunan Province,China;Center for Clinical Pharmacology,The Third Xiangya Hospital,Central South University,Changsha 410013,Hunan Province,China)

机构地区：[1]中南大学湘雅三医院肾内科,湖南长沙410013 [2]中南大学湘雅三医院临床试验研究中心,湖南长沙410013

出　　处：《中国临床药理学杂志》2021年第21期2985-2988,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(82173905);湖南省自然科学基金资助项目(20215580082)。

摘　　要：慢性肾病(CKD)是全球主要慢性疾病之一,临床药物治疗面临诸多难题。肠道微生物组作为人体重要的代谢"器官",与治疗CKD药物之间有着密切的相互作用。CKD药物可以塑造肠道微环境,影响肠道菌群的丰度及多样性。同时肠道微生物可以干预CKD治疗药物的代谢,影响药物疗效及毒副作用。靶向肠道菌群的药物优化和新药研发或将成为CKD治疗的有效策略。本文对其研究进展进行综述。Chronic kidney disease(CKD)is one of the world’s major chronic diseases,with many difficulties in the clinical drug therapy.Intestinal microbiome,as an important metabolic organ of the human body,has close interactions with drug metabolism.CKD drugs can shape the intestinal microenvironment and affect intestinal microbiota’s abundance and diversity.On the other hand,intestinal microbiota can interfere with the metabolism of CKD drugs and affect drugs’efficacy and side effects.Drug therapy optimization and new drug development by targeting intestinal microbiota could be a promising strategy for the therapy of CKD.In this narrative review,we conclude the advance in intestinal microbiota and drug therapy for CKD.

关 键 词：肠道菌群 慢性肾病 药物代谢 治疗 

分 类 号：R97[医药卫生—药品]